Junshi Biosciences Reports First Patient Dosed in Phase 3 JS207 Combination Trial
The Phase 3 trial is evaluating JS207 with JS007 as a first-line treatment for advanced hepatocellular carcinoma.
Related stories
Proya Shares Hit Limit Down, Fall 8.4% in Morning Trade
China cosmetics maker Proya traded at its daily limit-down level of 48.86 yuan, its lowest since Feb. 4, 2020, before closing the morning session down 8.4%. Citi cut its price targ
M impact | EQUITY | Oct 30, 2026, 04:46 AM UTC
Amazon Shares Fall 6% After Disappointing Wall Street
Amazon shares fell 6%, according to the headline.
M impact | EQUITY | Oct 30, 2026, 04:33 AM UTC
Asian session market picture: S&P 500 -0.91%, Nasdaq 100 -1.92%; USD/JPY -0.2%, WTI +1.15%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.91 percent, Nasdaq futures is down 1.92 percent, Dow futures is down 0.2 percent and Russell futures is do
M impact | EQUITY | Oct 30, 2026, 04:30 AM UTC
Indian shares inch higher as IT stocks and earnings rebound offset oil pressure
The Nifty 50 added 0.24% to 22,987.40 and the Sensex rose as IT stocks and post-results gains offset pressure from higher crude prices.
M impact | EQUITY | Oct 30, 2026, 04:29 AM UTC
Reliance Industries Q2 Profit May Top Rs 21,000 Crore
Reliance Industries is expected to report September-quarter profit above Rs 21,000 crore, with refining and Jio cited as earnings drivers. The company is scheduled to announce resu
M impact | EQUITY | Oct 30, 2026, 04:11 AM UTC
Australian Energy Stocks Reach One-Week High as Oil Rises
Australian energy stocks reached a one-week high as supply concerns lifted oil prices.
M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC